Alphatec (ATEC) to Release Earnings on Tuesday

Alphatec (NASDAQ:ATEC) is expected to release its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Alphatec to post earnings of $0.04 per share and revenue of $212.6740 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Alphatec Stock Up 2.0%

Shares of ATEC stock opened at $13.36 on Tuesday. The stock’s fifty day moving average price is $17.90 and its 200 day moving average price is $17.21. Alphatec has a 1-year low of $8.81 and a 1-year high of $23.29. The company has a market cap of $1.98 billion, a price-to-earnings ratio of -12.85 and a beta of 1.01. The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24.

Insider Buying and Selling at Alphatec

In related news, COO Scott Lish sold 19,900 shares of Alphatec stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $19.64, for a total value of $390,836.00. Following the completion of the transaction, the chief operating officer owned 641,432 shares in the company, valued at $12,597,724.48. The trade was a 3.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick Miles sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $21.01, for a total value of $2,101,000.00. Following the completion of the sale, the chief executive officer owned 5,135,398 shares of the company’s stock, valued at $107,894,711.98. This trade represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 2,281,125 shares of company stock worth $46,711,578. 22.80% of the stock is currently owned by company insiders.

Institutional Trading of Alphatec

Institutional investors have recently made changes to their positions in the company. Verition Fund Management LLC grew its holdings in shares of Alphatec by 8.9% during the fourth quarter. Verition Fund Management LLC now owns 140,355 shares of the medical technology company’s stock worth $2,953,000 after buying an additional 11,426 shares in the last quarter. Panagora Asset Management Inc. increased its position in Alphatec by 239.6% during the fourth quarter. Panagora Asset Management Inc. now owns 237,754 shares of the medical technology company’s stock worth $5,002,000 after purchasing an additional 167,754 shares during the last quarter. Mariner LLC acquired a new position in Alphatec in the fourth quarter valued at approximately $314,000. Barclays PLC increased its stake in Alphatec by 14.7% during the fourth quarter. Barclays PLC now owns 209,266 shares of the medical technology company’s stock worth $4,403,000 after acquiring an additional 26,826 shares during the last quarter. Finally, Morgan Stanley grew its holdings in shares of Alphatec by 22.0% during the 4th quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company’s stock worth $91,333,000 after purchasing an additional 784,191 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ATEC shares. TD Cowen reaffirmed a “buy” rating on shares of Alphatec in a research report on Tuesday, January 27th. Barclays lifted their price objective on shares of Alphatec from $23.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Canaccord Genuity Group upped their target price on Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Stifel Nicolaus initiated coverage on Alphatec in a research note on Tuesday, October 28th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus price target of $22.82.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.